Leaders in Life Sciences

著者： Dr. Kesha Chauhan MD
無料で聴く

  • サマリー

  • The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.

    Hosted on Acast. See acast.com/privacy for more information.
    Dr. Kesha Chauhan, MD
    続きを読む 一部表示

あらすじ・解説

The Leaders in Life Sciences podcast features daily news, strategies, interviews with healthcare professionals, and life science executives. This show is for commercial and medical leaders who want to stay up to date and inspired in their daily work.

Hosted on Acast. See acast.com/privacy for more information.
Dr. Kesha Chauhan, MD
政治・政府 生物科学 科学 衛生・健康的な生活 身体的病い・疾患
続きを読む 一部表示
エピソード
  • 29: Another Recall for Glenmark: Millions of Bottles of Generic ADHD Drug Pulled

    29: Another Recall for Glenmark: Millions of Bottles of Generic ADHD Drug Pulled
    2025/03/17
    Glenmark Pharmaceuticals has recalled nearly 1.5 million bottles of generic atomoxetine (ADHD medication) due to unacceptable levels of a potential carcinogen, N-nitroso atomoxetine. This recall, from January 2024, adds to a series of recent recalls by Glenmark, including potassium chloride capsules (June 2024), diltiazem hydrochloride (December 2024), and various other drugs in 2023 and 2022, due to manufacturing and impurity issues. These repeated recalls raise concerns about Glenmark's quality control, and patients taking Glenmark's atomoxetine are advised to consult their healthcare providers.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    5 分
  • 28: Novo Nordisk's Bold Leap into Rare Diseases

    28: Novo Nordisk's Bold Leap into Rare Diseases
    2025/03/12
    Novo Nordisk is strategically expanding into rare diseases, shifting from its traditional focus on common chronic conditions, by significantly increasing R&D investment and executing key acquisitions to build a strong portfolio in blood, endocrine, and hemato-renal disorders. The company aims to achieve long-term leadership in this space through internal innovation, strategic partnerships, and further mergers and acquisitions.

    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    9 分
  • 27: FDA Updates Labeling and Safety Information For Testosterone Products

    27: FDA Updates Labeling and Safety Information For Testosterone Products
    2025/03/05

    The FDA is updating the labeling for all FDA-approved testosterone products (oral, topical gel, transdermal patch, buccal system, and injection) based on the TRAVERSE trial and ABPM studies. The results of the TRAVERSE trial are being added to all testosterone product labels, and the language in the Boxed Warning related to an increased risk of adverse cardiovascular outcomes will be removed from all testosterone products. The TRAVERSE trial found no increased risk of adverse cardiovascular outcomes in men using testosterone for hypogonadism.

    However, the "Limitation of Use" language for age-related hypogonadism is being retained. A new warning about increased blood pressure is being added to products without such a warning. Furthermore, product-specific information on increased blood pressure will be included for products with completed ABPM studies. ABPM studies confirmed an increase in blood pressure with the use of all testosterone products. These actions follow prior FDA warnings about the risks of stroke, heart attack, and death in men taking testosterone products. Testosterone is only approved for use in men with low testosterone levels in conjunction with an associated medical condition.


    Hosted on Acast. See acast.com/privacy for more information.
    続きを読む 一部表示
    6 分

Leaders in Life Sciencesに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。